加载中
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
最新数据
US$20.255
−US$0.825 · -3.91%
盘中时间采用ET。市场数据可能有所延迟。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
盘中时间采用ET。市场数据可能有所延迟。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 18.1万 USD | 83万 USD | 49万 USD | 44.1万 USD |
| 毛利 | — | −18.1万 USD | −83万 USD | −49万 USD | −44.1万 USD |
| 研究与开发 | 2.01亿 USD | 639.8万 USD | 2377万 USD | 4820.6万 USD | 3848.8万 USD |
| 销售、一般及管理费用 | 968.5万 USD | 1031.8万 USD | 1185.7万 USD | 1251.1万 USD | 1329.8万 USD |
| 营业费用 | 2.11亿 USD | 1671.6万 USD | 3562.7万 USD | 6071.7万 USD | 5178.6万 USD |
| 利息收入 | 116.7万 USD | 84.4万 USD | 168.9万 USD | 72.2万 USD | 15.6万 USD |
| 折旧和摊销 | 3.4万 USD | 18.1万 USD | 83万 USD | 49万 USD | 44.1万 USD |
| 营业利润 | −2.11亿 USD | −1689.7万 USD | −3645.7万 USD | −6120.7万 USD | −5222.7万 USD |
| 净利润 | −2.1亿 USD | −2143.9万 USD | −3834.9万 USD | −6162.4万 USD | −5175.2万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$50.00
上涨空间 146.85%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM2608.72万0.03%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1501.94万0.15%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Russell 2000 ETFVTWO864.8万0.05%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO636.41万0.05%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Extended Market ETFVXF605.57万0.01%954亿 USD0.05%US$233.52-0.63%
Schwab U.S. Small-Cap ETFSCHA531.4万0.02%217.13亿 USD0.03%US$32.66-0.40%
iShares Core S&P Total U.S. Stock Market ETFITOT150.2万0.00%980.88亿 USD0.03%US$169.43-0.14%
Vanguard Russell 2000 Growth ETFVTWG113.48万0.06%17亿 USD0.06%US$258.28-0.85%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Core S&P Total U.S. Stock Market ETFITOTVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
